A Study Of PF-04449913 In Select Hematologic Malignancies

Completed · Phase 1

Conditions studied: Hematologic Malignancies

In brief

This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies.

Key facts

Study ID

NCT00953758

Run by

Pfizer

People needed

47

Starts

2010-03-03

Expected to finish

2013-02-27

Last updated by the study team

2024-04-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with select advanced hematologic malignancies who are refractory, resistant or intolerant to prior therapies. They may be newly diagnosed and previously untreated, but not eligible for standard treatment options, or for whom standard therapies are not anticipated to result in a durable response.
• ECOG performance status 0 to 2
• Adequate organ function

You may not qualify if…

• Patients with active CNS disease
• Patient with active malignancy with the exception of basal cell carcinoma, non melanoma skin cancer, carcinoma in situ cervical or skin cancer
• Active GVHD other than Grade 1 skin involvement
• Known malabsorption syndrome
• Patient has an active, life threatening or clinically significant uncontrolled systemic infection

Where it is running

• UCSD Medical Center - La Jolla — La Jolla, California, United States
• Moores UCSD Cancer Center — La Jolla, California, United States
• UCSD Medical Center - Hillcrest — San Diego, California, United States
• The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States
• University of Washington Medical Center, Seattle Cancer Care Alliance — Seattle, Washington, United States
• U.O. di Ematologia — Bologna, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.